BARD1 Life Sciences Limited Closed The Entitlement Offer


The biotechnology company situated in Australia has announced that the non-renounceable Entitlement Offer to raise approximately $3.3 million, closed at 2:00 pm on Monday, 10 December 2018 as per the terms of the Offer. To subscribe for 59,141,273 new Shares from eligible shareholders under the Offer raising $1,184,484.26 the company has received applications. With the fully paid ordinary shares of the company existing, all new shares issued under the Entitlement Issue will rank equally in all respects.

The company entered into a mandate letter as outlined in the Offer Document with Merchant Corporate Advisory Pty Ltd who have agreed under the Mandate to subscribe for and place all Shortfall Shares under the Offer. Dr. Irmgard Irminger-Finger, the Executive Director, has sold 8,599,683 shares in the company and said that to enable her to participate in the company’s non-renounceable rights issue which was announced on 08/11/2018 she has sold the shares.  [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

The company focused on developing non-invasive diagnostics for early detection of cancer to save lives. BARD1 blood tests measure autoantibodies to BARD1 proteins and use an algorithm to give a cancer score. Present in early stages before symptoms appear autoantibodies indicate the body’s early immune response to cancer. Early detection enables earlier treatment, save lives, improves patient outcomes and reduces healthcare costs.

Bard 1 for further expansion of its product portfolio, diversification of its risk profile and enhancing shareholder value, continued with its plan to explore varied corporate and fundraising opportunities. As on September 30, 2018 i.e. at the end of the first quarter, the company has posted a closing cash balance at $1.13m.

BARD1 Life Sciences Limited (ASX: BD1) is trading at a market price of $0.019 which is flat for the day as at December 12, 2018. The market capitalization of the stock is at $15.74 billion as of the date, and the company has witnessed an attractive performance change of 177.45% over the past 12 months.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report